Nuosheng Medical shines at CUA | Minimally invasive technology innovation, technology covers the globe
The 32nd Urological Academic Conference (CUA 2025), sponsored by the Chinese Medical Association and the Urology Branch of the Chinese Medical Association (CUA), organized by the Liaoning Medical Association and the Urology Branch of the Liaoning Medical Association, and co - organized by the Second Affiliated Hospital of Dalian Medical University, successfully concluded in Dalian.
This prestigious event brought together top experts and scholars in the field of urology both at home and abroad. They engaged in in - depth exchanges and discussions centered around core themes such as "Innovation of Minimally Invasive Techniques", "Precise Tumor Therapy", and "Functional Preservation Strategies".
Experts recognition
Professor Huang Jian from Sun Yat - sen Memorial Hospital of Sun Yat - sen University, Academician Zhang Xu from Chinese People's Liberation Army General Hospital, Zheng Junhua from Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (hereinafter referred to as Shanghai Renji Hospital), Xie Liping from the First Affiliated Hospital of Zhejiang University School of Medicine, and many other conference committee members attended the opening ceremony. Academician Zhang Xu, during his speech, particularly emphasized that the independently - developed equipment of Nortion Medical represents China's scientific and technological level. He expressed his anticipation that this technology will go global in the future, expanding beyond China's borders.
A total of over 20 authoritative experts were invited to the conference. They shared and discussed from multiple aspects, including the interpretation of the "Expert Consensus", technical advantages, and clinical applications. The conference hall was filled to capacity, and the participating experts interacted actively, showing a strong interest in this innovative technology.
Authoritative Interpretation
Professor Xue Wei, the vice dean of Shanghai Renji Hospital, conducted an in - depth interpretation of the "Expert Consensus on the Treatment of Prostate Diseases with Irreversible Electroporation (IRE)" at the main conference venue. He systematically elaborated on the indication selection, operation specifications, and efficacy evaluation criteria of IRE technology. Professor Xue stressed that as a technology developed in China, IRE can benefit patients with localized prostate cancer (low - to - intermediate risk) and some selectively high - risk patients, especially those who require the preservation of sexual function and urinary continence.
Clinical Practice
At this conference, Professor Dong Bojun from Shanghai Renji Hospital and Professor Yang Jun from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology were especially invited. Based on cases from their respective hospitals, they shared their experiences in dealing with special patients in clinical practice and the excellent follow - up results of postoperative patients.
In the session chaired by Professor Shen Wenhao from Southwest Hospital of Army Medical University, numerous young doctors were also invited to participate and share their personal insights. The on - site interaction was vibrant.
Academic Interaction
This time, Nortion Medical invited a number of young and middle - aged doctors, along with experts and surgeons from different cities and hospitals who possess rich experience in irreversible electroporation technology. They gathered to share their experiences and insights regarding the application of this technology in the fields of prostate cancer and benign prostatic hyperplasia.
Although CUA2025 has come to a close, the exploration of precision therapy by Nortion Medical will never stop
In the future, Nortion Medical will continue to collaborate with clinical experts to promote the innovation and popularization of IRE technology in the field of urology. It aims to bring more precise, safe, and efficient treatment solutions to patients. By continuously investing in research and development and working side - by - side with clinical experts, we are committed to writing a new chapter in the treatment of prostate diseases.
